Abstract #1151

Evaluation of CEST-mDixon imaging for breast malignancy characterization and staging: correlation with histopathology

Ioannis Papadopoulos¹, Ivan Dimitrov², Jochen Keupp³, Durga Udayakumar^1,4, Stephen Seiler¹, Sunati Sahoo⁵, Yin Xi¹, Emily Knippa¹, Robert Lenkinski^1,4, Ananth Madhuranthakam^1,4, Shu Zhang⁶, and Elena Vinogradov^1,4

¹Radiology, University of Texas Southwestern Medical Center, Dallas, TX, United States, ²Philips Healthcare, Gainesville, FL, United States, ³Philips Research, Hamburg, Germany, ⁴Advanced Imaging Research Center, University of Texas Southwestern Medical Center, Dallas, TX, United States, ⁵Pathology, University of Texas Southwestern Medical Center, Dallas, TX, United States, ⁶Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, TX, United States

CEST-mDixon imaging utilizing hydroxyl and amine pools could aid breast tumor diagnosis, as shown in previous preliminary studies. In the current study, CEST-mDixon is evaluated in a breast cancer patient cohort using improved saturation and acquisition parameters. The results agree with previous findings demonstrating moderate linear correlation of CEST effects at 1 ppm and 2 ppm with Ki-67. In addition, we observe a linear correlation with the percentage of cells positive for nuclear expression of the progesterone receptor (PR), the first such observation reported. Overall, the study confirms the potential for CEST-mDixon for characterizing breast tumor aggressiveness non-invasively.

This abstract and the presentation materials are available to members only; a login is required.

Join Here